The Australian Sensor-Augmented Pump Algorithm Study

Phase 4

Completed

• Conditions: Type 1 diabetes; Glycaemic control.; Oxidation; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12607000198426
• Lead Sponsor: St Vincents Hospital Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-04-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Type I diabetes (c-peptide negative)- English speaking. Established on pump therapy for at least 3 months and be proficient in the use of an insulin dose calculator. -Proficient at and committed to at least four fingerprick glucose measurements per day.-Willing to use MiniMed MMT 722 glucose sensor >70% of study time period.-Current HbA1c of <9.5% -All should have access to electronic communication ie email.

Exclusion Criteria

Visual Impairment such that the patient is unable to see the screen or fill the reservoir of the CSII device, or read a glucometer display or administer insulin safely using a pen device.- Intellectual or language difficulties such that operation of a CGM or CSII device is precluded.-Significant renal impairment (eGFR <60 mL/min/1.73 m2 )-Eating Disorders.-Major Psychiatric Disorders.-Life threatening illness (eg myocardial infarct) within last three months.- Steroid therapy or the presence of disease states likely to require future steroid therapy.-Abnormal thyroid function.-A history of gastroparesis or delayed gastric emptying.-Untreated/ inadequately treated coeliac disease.-Pregnancy. For women of childbearing age appropriate contraceptive measures should be taken.- A documented history of insulin allergy/ antibodies.-Patients with haemoglobinopathies or patients requiring regular transfusions.

Study & Design

• Study Type: Interventional
• Study Design: Not specified